Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Simiao CaoNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Guoxuan BaiNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.ORCID 0009-0006-8758-6316
Qimuge WuriNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Jiayin LiNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Xiaojing ZhangNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Zhilin HanNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Hui WuNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Jiaxin WuNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Chu WangNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.ORCID 0009-0009-9202-677X
Xianghui YuNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.ORCID 0000-0001-7739-1386
Haihong ZhangNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.ORCID 0000-0002-3074-1817
Funding
Jilin Province Science and Technology Department 20240402044GH
6 · The paper itself
Abstract
DNA-based cancer vaccines represent a safe and promising immunotherapeutic strategy, but their clinical efficacy is often limited by weak immunogenicity, primarily due to inefficient antigen cross-presentation. To overcome this challenge, the MHC class I trafficking domain (MITD) can be fused to tumor antigens to enhance their intracellular routing in dendritic cells (DCs), thereby promoting the efficiency of cross-presentation. In addition, incorporation of CD4
Indexed as
Cancer VaccinesEpitopes, T-LymphocyteHistocompatibility Antigens Class IPancreatic NeoplasmsVaccines, DNAAnimalsAntigens, NeoplasmCell Line, TumorDendritic CellsDeoxycytidineDisease Models, AnimalFemaleGemcitabineGPI-Linked ProteinsHumansMesothelinAntigens, NeoplasmCancer VaccinesDeoxycytidineEpitopes, T-LymphocyteGemcitabineGPI-Linked ProteinsHistocompatibility Antigens Class IMesothelinMsln protein, mouseVaccines, DNAcross-presentationDNA vaccinesimmunotherapyMITDPADRE
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A DNA Vaccine Incorporating the MHC Class I Trafficking Domain and PADRE Epitope Enhances Antitumor Immunity in a Murine Pancreatic Cancer Model. · full record | OpenQuestion